NEW YORK, Oct. 2 – Sequenom said Tuesday it had sold 10 of its MassArrray gene analysis systems to a variety of companies and institutions during the third quarter, bringing the number of systems sold to 48.
San Diego-based Sequenom said in a statement that the new customers include Pfizer, the Department of Molecular and Human Genetics, Baylor College of Medicine, Children's Hospital Boston, the Genome Institute of Singapore, the Institute of Biomedical Sciences, Academia Sinica, and the Partners HealthCare/Harvard Medical School Genotyping Center.
Sequenom also said that the Sanger Center and the National Institutes of Health have each purchased additional systems. The NIH placed the additional system at its National Institute of Arthritis and Musculoskeletal and Skin Diseases. Five of Sequenom’s customers have multiple systems.
The MassArray system, first commercialized in early 2000, provides a platform for genotyping experiments without the use of fluorescence or other tagging techniques. Instead, the company's technology applies MALDI-TOF mass spectrometry directly to fragments of DNA to detect SNPs.
Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million, depending on consumables.
In addition, Sequenom said that sales of its SpectroChip high-density launching pads were up 28 percent compared with the previous quarter.